This proposal "tyrosine kinases and prostate cancer" began in 1998 with the development of tyrosine kinase display approach and the first comprehensive tyrosine kinase profile of prostate cancer cells. In the ensuing years, tyrosine kinases involved in androgen independence were identified and the processes characterized. This led to the discovery of Src tyrosine kinase (TK) complex as a central integrator of signals emanating from tyrosine kinase receptor, cytokine receptor and G-protein coupled receptor. Recent studies from several labs including the PI's showed that Src activation is frequently found in castration resistant prostate cancer and Src signatures are found in most metastatic tumors including those which lack androgen receptor expression. The Src TK complex presents novel targets for potential therapeutic intervention. A number of Src inhibitors have entered clinical trials including one based on our study. However, as a monotherapy, Src-targeting therapy has met with limited success, and there is a need for improvement. In the past grant period, with an emphasis on translational research, we have focused on Src selective inhibitors as a potential therapy for prostate cancer and as a probe for critical src-mediated signal pathways involved in prostate cancer progression. We have made significant progress with the major discovery of autophagy as an underlying mechanism of prostate cancer cell's resistance to apoptosis induced by Src-targeting therapy. We also identified several signal pathways associated with Src-mediated prostate carcinogenesis. Built upon the progress made in the past three years, the present proposal continues to focus on the discovery of novel Src oncogenic pathway and the improvement of Src inhibitor-based therapy. Specifically, we will study a new signal pathway which connects Src to ERG via microRNA modulation and the improvement of Src targeting therapy by a combination of autophagy modulators.

Public Health Relevance

The most troubling aspect of prostate cancer is the development of highly metastatic, castration-resistant tumors, which at present are incurable. Src tyrosine kinase is an integrator of oncogenic signals and its activation is a hall mark of metastatic, castration-resistant prostate cancers. We showed that Src is involved in androgen receptor activation in the absence of androgen, contributing to the development of castration-resistant prostate cancer. Others showed that androgen receptor negative metastatic tumors exhibit Src signatures indicating Src activation is involved in sustaining these tumors. Thus, Src signals may be involved in both early and late stage of prostate carcinogenesis. The application or Src-targeting therapy thus deserves attention. However, thus far, clinical trials using Src (or for that matter other tryrosine kinase) inhibitor as monotherpay has met with limited success. The present proposal is specifically designed to improve Src-targeting therapy based on the laboratory discoveries and progress made in the past grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA165263-15
Application #
8636409
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Salnikow, Konstantin
Project Start
1997-07-24
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
15
Fiscal Year
2014
Total Cost
$309,964
Indirect Cost
$108,689
Name
University of California Davis
Department
Biochemistry
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Wang, Ling-Yu; Hung, Chiu-Lien; Chen, Yun-Ru et al. (2016) KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Cell Rep 16:3016-27
Kuo, Ching-Ying; Cheng, Chun-Ting; Hou, Peifeng et al. (2016) HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. Oncotarget 7:34052-69
Wang, Junjian; Wang, Haibin; Wang, Ling-Yu et al. (2016) Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ 23:1886-1896
Wang, Junjian; Zou, June X; Xue, Xiaoqian et al. (2016) ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 22:488-96
Shi, Xu-Bao; Ma, Ai-Hong; Xue, Lingru et al. (2015) miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res 75:5309-17
Shih, Jing-Wen; Wang, Ling-Yu; Hung, Chiu-Lien et al. (2015) Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. Int J Mol Sci 16:28943-78
Chandrasekar, Thenappan; Yang, Joy C; Gao, Allen C et al. (2015) Targeting molecular resistance in castration-resistant prostate cancer. BMC Med 13:206
Chandrasekar, Thenappan; Yang, Joy C; Gao, Allen C et al. (2015) Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4:365-80
Wang, Hung-Jung; Hsieh, Ya-Ju; Cheng, Wen-Chi et al. (2014) JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1*-mediated glucose metabolism. Proc Natl Acad Sci U S A 111:279-84
Hung, Chiu-Lien; Wang, Ling-Yu; Yu, Yen-Ling et al. (2014) A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A 111:18697-702

Showing the most recent 10 out of 15 publications